Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis.
5 Repeated evidence
- Type of study
- meta-analysis or systematic review
- Studied in
- people
- Participants
- not stated in the abstract
- Published
- 2017 in Climacteric : the journal of the International Menopause Society
- Cited
- 2 times by other research
- Who paid
- Not declared. PubMed carries no conflict-of-interest statement for most articles; that is not the same as independent.
- Source
- PubMed 27593417 · doi 10.1080/13697137.2016.1221919
OBJECTIVES: Transdermal hormone replacement therapy is preferred for menopausal vasomotor symptoms. Our purpose was to compare the efficacy and local tolerability of a patch and a metered-dose transdermal spray that have never been directly compared. METHOD: The relative change in the number of hot flushes between baseline and week 12 was selected as an efficacy indicator and the frequency of local skin reactions as a tolerability indicator. A network meta-analysis was performed to compare efficacy. Application site tolerability was compared descriptively. RESULTS: Overall 46 studies were identified. In the efficacy analysis, eight active treatment arms and a placebo arm were determined based on the estradiol daily dose (from 14 μg to 50 μg). All but one had a significantly higher effect on relative change in the number of hot flushes than did the placebo. We found no evidence for different efficacy of the patch and the metered-dose transdermal spray. The latter performed better in terms of local skin reactions. CONCLUSION: The patch and the metered-dose transdermal spray seem to have the same efficacy on vasomotor symptoms in estradiol hormone replacement. The local tolerability of the metered-dose transdermal spray is favorable.